Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
168.6 USD | +1.89% | +7.84% | +8.78% |
12:00pm | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Jun. 06 | AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint | MT |
ETFs positioned on AbbVie Inc.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.54% | 12 M€ | +15.09% | - | |
1.45% | 104 M€ | +10.63% | ||
1.39% | 2 M€ | +21.73% | - | |
1.35% | 1,448 M€ | -.--% | - | |
1.35% | 219 M€ | +17.17% | - | |
1.34% | 330 M€ | -.--% | ||
1.30% | 110 M€ | +11.54% | - | |
1.30% | 800 M€ | +4.45% | ||
1.24% | 85 M€ | +16.00% | - | |
1.18% | 655 M€ | -.--% | - | |
1.18% | 273 M€ | -.--% | ||
1.18% | 1,174 M€ | +23.54% | ||
1.16% | 24 M€ | 0.00% | - | |
1.16% | 224 M€ | +3.83% | - | |
1.16% | 26 M€ | +0.30% | - | |
1.06% | 375 M€ | +8.49% | ||
1.02% | 26 M€ | +23.61% | - | |
1.00% | 276 M€ | +11.40% | - | |
0.96% | 1 M€ | +0.04% | ||
0.94% | 1,848 M€ | +18.39% | - | |
0.94% | 559 M€ | +14.30% | ||
0.91% | 204 M€ | +10.54% | ||
0.90% | 6 M€ | +17.98% | - | |
0.89% | 121 M€ | +8.99% | - | |
0.87% | 1,487 M€ | +8.44% | - | |
0.81% | 8 M€ | +7.96% | - | |
0.81% | 744 M€ | +10.15% | ||
0.78% | 265 M€ | +4.29% | - | |
0.74% | 50 M€ | +12.23% | ||
0.73% | 205 M€ | -.--% | ||
0.72% | 9 M€ | +10.29% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.78% | 298B | |
+43.64% | 754B | |
+40.45% | 630B | |
-6.58% | 352B | |
+19.72% | 331B | |
+18.53% | 250B | |
+12.16% | 217B | |
-0.61% | 216B | |
+6.13% | 164B | |
+0.03% | 163B |
- Stock Market
- Equities
- ABBV Stock
- Funds and ETFs AbbVie Inc.